CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 300 enrolled
Drug / intervention
Fluarix™ +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00374842
NCT00374842Phase 2Completed
CompareCT.gov

A Study to Evaluate the Immunogenicity, Safety and Reactogenicity of Adjuvanted Influenza Vaccine Candidates Compared to Fluarix™ Administered Intramuscularly in Subjects Aged 18-59 Years.

GlaxoSmithKline·interventional·Posted Sep 12, 2006·Updated Jun 8, 2018

In Brief

A Phase 2 clinical trial evaluating Fluarix™ and GSK1247446A for Influenza. Completed, enrolled 300 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the immunogenicity and the safety of candidate vaccines compared to Fluarix™ administered intramuscularly in subjects aged 18-59 years

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesBelgium
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 12, 2006
Enrollment StartOct 3, 2006
Primary CompletionNov 1, 2006
Study CompletionNov 30, 2006
TodayJul 2, 2026
Enrollment to primary: 28 daysPosted 19.8 years ago

Interventions

Fluarix™biological

GlaxoSmithKline Biologicals' licensed influenza vaccine

GSK1247446Abiological

Low-dose GlaxoSmithKline Biologicals' GSK1247446A influenza vaccine